Method characteristics of dideoxy-sequencing, DxS-KRAS and KRAS-TMGB in diagnostic KRAS mutation assessment (KRAS codons 12 and 13).

* = results may not be accurate in cases with tumor cell content below the selectivity of this method, even in samples with preserved DNA& = reported by the manufacturerˆ = failure to obtain results necessitates troubleshooting at each of the multiple steps of this method; DNA extraction had also to be repeated in some cases# = one successful assessment is meant; cost compared to sequencing with analogies according to reagent prices in Greece

*：当肿瘤细胞含量低于本方法的检测选择性阈值时，即便DNA保存完好的样本，其检测结果亦可能不准确。
&：该说明由制造商提供。
ˆ：若未获得有效检测结果，需对本实验方法的全部步骤逐一排查；部分案例中还需重新提取DNA。
#：此处指代单次成功评估；成本对比参照希腊地区的试剂价格，类比测序方法进行核算。